Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant combinations in metastatic colorectal cancer
NCT04660812Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of etrumadenant in metastatic colorectal cancer (mCRC) (4 cohorts), sponsored by Arcus Biosciences. Primary endpoints: Progression-Free Survival, Objective Response Rate and 1 more. Started May 2021; status: completed.
02
Drugs
etrumadenant
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04660812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660812.